Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Inger Johanne Zwicky Eide, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicėnas, Jussi Koivunen, Bjørn Henning Grønberg, Odd Terje Brustugun
Topics & Concepts
OsimertinibT790MMedicineLung cancerInternal medicineOncologyClinical endpointAcquired resistanceClinical trialCancerAdenocarcinomaROS1Lung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Diagnosis and Treatment